北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 血液科  > 期刊论文
学科主题: 临床医学
题名:
Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL
作者: Sun, Y-Q1,2; Wang, J.1,2; Jiang, Q.1,2; Xu, L-P1,2; Liu, D-H1,2; Zhang, X-H1,2; Liu, K-Y1,2; Huang, X-J1,2,3
刊名: BONE MARROW TRANSPLANTATION
发表日期: 2015
DOI: 10.1038/bmt.2014.195
卷: 50, 期:1, 页:20-25
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
研究领域[WOS]: Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation
关键词[WOS]: ACUTE LYMPHOBLASTIC-LEUKEMIA ; STEM-CELL TRANSPLANTATION ; HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; SINGLE-CENTER ; REMISSION ; OUTCOMES ; RELAPSE ; MULTICENTER ; EXPERIENCE
英文摘要:

Only 30% of high-risk adult ALL patients in their first complete remission (CR1) are able to receive an HLA-matched sibling stem cell transplant. The role of haploidentical hematopoietic SCT (haplo-HSCT) in post-remission therapy is not well established. Recently, we developed a novel protocol for unmanipulated haploidentical transplantation. In this study, we compared haplo-HSCT with conventional consolidation and maintenance chemotherapy in adult high-risk ALL patients. Between January 2000 and December 2012, 104 patients received conventional chemotherapy and 79 patients received haplo-HSCT. Patients who underwent haplo-HSCT had significantly improved 3-year OS (72.5% vs 26.6%; P < 0.001), 3-year disease-free survival (DFS) (63.9% vs 21.1%; P < 0.001) and 3-year relapse (18.7% vs 60.5%; P < 0.001) rates. The non-relapse mortality (NRM) rate was not different between patients treated with haplo-HSCT vs chemotherapy (19.2% vs 14.4%; P = 0.80). In multivariate analysis, the only factor associated with improved OS, better DFS and low risk of relapse was haplo-HSCT. The only factor associated with high NRM was enrollment before 2006. In conclusion, haplo-HSCT may be an option for adults with high-risk ALL in CR1 who do not have an HLA-matched donor.

语种: 英语
WOS记录号: WOS:000347806800005
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/59716
Appears in Collections:北京大学第二临床医学院_血液科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Tsinghua Ctr Life Sci, Beijing, Peoples R China
2.Peking Univ, Peoples Hosp, Inst Hematol, Beijing 100044, Peoples R China
3.Beijing Key Lab Hematopoiet Stem Cell Transplanta, Beijing, Peoples R China

Recommended Citation:
Sun, Y-Q,Wang, J.,Jiang, Q.,et al. Haploidentical hematopoietic SCT may be superior to conventional consolidation/maintenance chemotherapy as post-remission therapy for high-risk adult ALL[J]. BONE MARROW TRANSPLANTATION,2015,50(1):20-25.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Sun, Y-Q]'s Articles
[Wang, J.]'s Articles
[Jiang, Q.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Sun, Y-Q]‘s Articles
[Wang, J.]‘s Articles
[Jiang, Q.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace